TACE联合缓释化疗粒子(5-Fu)治疗原发性肝癌的临床研究  

A Clinical Study on TACE combined with Slow-released 5-fluorouracil for Hepatocellular Carcinoma

作　　者：郭青 董方晓 栾翠美 颜玉茂 

机构地区：[1]烟台市传染病医院放射科,山东264001

出　　处：《当代医学》2010年第17期302-304,共3页Contemporary Medicine

摘　　要：目的评价肝动脉化疗栓塞术(TACE)、肝动脉化疗栓塞联合5-FU缓释粒子(TACE+5-FU)的综合介入治疗方法治疗肝癌的疗效,为临床合理化治疗方案的确定提供参考与帮助。方法 192例原发性肝癌分成TACE组(A组)及TACE+缓释粒子(5-FU)组(B组),对不同治疗手段疗效进行比较分析。结果治疗后A、B组1年生存率分别为69.02%、83.54%,2年生存率分别为26.54%、40.5%,3年生存率分别为7.9%、17.72%,A、B组术后1年复发率分别为60.33%、49.28%,术后2年复发率分别为76.59%、61.24%。结论 TACE+缓释粒子(5-FU)Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization（TACE） combined with slow-released 5-fluorouracil in the comprehensive Interventional treatment of hepatocellular carcinoma（HCC） to find the better therapeutic program for clinical use.Methods 192 patients with primary hepatocellular carcinoma were divided into two groups.TACE was Group A,group B was TACE＋5-FU.Results The 1-year survival rates of 2 group were 69.02%,83.54% and 2-year survival rates of 2group were 26.54%,40.5% and 3-year survival rates of 2 group were 7.9%,17.72% respectively.The post-treatment recurrent rates of group A and B were 60.33%,49.28% for one year,76.59%,61.24% for two years respectively.Conclusion For primary hepatocellular carcinoma,TACE with slow-released 5-fluorouracil is a better method than TACE only.

关 键 词：原发性肝癌:介入 5-氟尿嘧啶缓释粒子 经导管动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤]